Protective effects of glycyrrhizic acid by rectal treatment on a TNBS-induced rat colitis model

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 3, 2011, Pages 439-446

  Liu, Ying ^a   Xiang, Jin ^a   Liu, Min ^a   Wang, Shi ^a   Lee, Robert J ^b   Ding, Hong ^a  

^a WUHAN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Colitis; Glycyrrhizic acid; Immunoregulation; Rectal administration

Indexed keywords

ALCOHOL; GLYCYRRHIZIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOREGULATION; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; RAT; SPLEEN LYMPHOCYTE;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCYRRHIZIC ACID; INTERLEUKIN-10; INTERLEUKIN-6; MACROPHAGES; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; SPLEEN; TRINITROBENZENESULFONIC ACID;

EID: 79952207513     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01185.x     Document Type: Article

References (47)

1. Martin AR et al. The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 2003; 481: 281-291. (Pubitemid 37464980)
2. Qin OY et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006; 21: 1772-1782.
3. Westbrook AM et al. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 2009; 69: 4827-4834.
4. Inoue S et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 1999; 94: 2441-2446. (Pubitemid 29420671)
5. Katz JA et al. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 1999; 15: 291-297. (Pubitemid 29377246)
6. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 2003; 9: 1107-1113. (Pubitemid 36443211)
7. Vermeire S et al. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3.
8. Yadav VR et al. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech 2009; 10: 752-762.
9. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 622-635. (Pubitemid 32171636)
10. Hagar HH et al. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol 2007; 554: 69-77. (Pubitemid 44822587)
11. Chung JG et al. Inhibition of N-acetyltransferase activity and DNA-2-aminofluorene adducts by glycyrrhizic acid in human colon tumour cells. Food Chem Toxicol 2000; 38: 163-172. (Pubitemid 30136267)
12. Hoever G et al. Antiviral activity of glycyrrhizic acid derivatives against SARS - coronavirus. J Med Chem 2005; 48: 1256-1259. (Pubitemid 40270469)
13. Abe K et al. Glycyrrhizin prevents of lipopolysaccharide/d-galactosamine- induced liver injury through down-regulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol 2008; 60: 91.
14. Yuan H et al. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol 2006; 12: 4578-4581. (Pubitemid 44256351)
15. Elliott DE et al. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G385-G391. (Pubitemid 36227886)
16. Arita M et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005; 102: 7671-7676. (Pubitemid 40741029)
17. Bouma G et al. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology 2002; 123: 554-565. (Pubitemid 34827199)
18. Lee S et al. 2′, 4′, 6′-Tris (methoxymethoxy) chalcone protects against trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis factor- -induced intestinal epithelial inflammation via heme oxygenase 1-dependent and independent pathways. Biochem Pharmacol 2007; 74: 870-880. (Pubitemid 47212081)
19. Chevalier E et al. Beneficial effect of trimebutine and N-monodesmethyl trimebutine on trinitrobenzene sulfonic acid-induced colitis in rats. Life Sci 2004; 76: 319-329. (Pubitemid 39452913)
20. Lowry O et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
21. Misra H, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175.
22. Ohkawa H et al. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358. (Pubitemid 9194347)
23. Mahgoub AA et al. Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett 2003; 145: 79-87. (Pubitemid 38366131)
24. Jagtap AG et al. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol 2004; 90: 195-204. (Pubitemid 38180477)
25. Ha CL et al. Immunomodulatory effect of Glossogyne tenuifolia in murine peritoneal macrophages and splenocytes. J Ethnopharmacol 2006; 107: 116-125.
26. Hansen MB et al. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-210. (Pubitemid 19132276)
27. Zimecki M et al. Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation. Cell Mol Biol Lett 2003; 8: 699-712.
28. Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 1995; 269: G119-G11G.
29. Martin AR et al. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004; 67: 1399-1410. (Pubitemid 38315105)
30. Gearry RB et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006; 12: 936-943. (Pubitemid 44498282)
31. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996; 184: 241-251.
32. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 21-33.
33. Burich A et al. Helicobacter-induced inflammatory bowel disease in IL-10-and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol 2001; 281: G764-G778.
34. Liu BG et al. Altered protein profile of lymphocytes in an antigen-specific model of colitis: a comparative proteomic study. Inflamm Res 2007; 56: 377-384.
35. Boyle NT, Connor TJ. MDMA ('Ecstasy') suppresses innate IFN-gamma production and signalling, and inhibits MHC II expression on APCs. Eur Neuropsychopharmacol 2006; 16(Suppl. 1): 25-26.
36. Feng C et al. Diammonium glycyrrhizinate, a component of traditional Chinese medicine Gan-Cao, prevents murine T-cell-mediated fulminant hepatitis in IL-10- and IL-6-dependent manners. Int Immunopharmacol 2007; 7: 1292-1298. (Pubitemid 47126367)
37. Neurath MF. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001; 22: 225-225.
38. Chen KY et al. Activation of nuclear factor-kappa B and effects of pyrrolidine ithiocarbamate on TNBS-induced rat colitis. World J Gastroenterol 2005; 11: 1508-1514.
39. Bossone C et al. Alterations in spontaneous contractions in vitro after repeated inflammation of rat distal colon. Am J Physiol Gastrointest Liver Physiol 2001; 280: G949-G957.
40. Arulampalam V, Pettersson S. Uncoupling the p38 MAPK kinase in IBD: a double edged sword? Gut 2002; 50: 446-447. (Pubitemid 34638857)
41. Siegmund B. Interleukin-1 beta converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 2002; 64: 1-8. (Pubitemid 34775170)
42. Maihofner C et al. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 2003; 24: 665-671. (Pubitemid 36592401)
43. Duque J et al. Up-regulation of cyclooxygenase-2 by interleukin-1 beta in colon carcinoma cells. Cell Signal 2006; 18: 1262-1269. (Pubitemid 44275220)
44. Travis S et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005; 11: 713-719. (Pubitemid 41271174)
45. Størmer F et al. Glycyrrhizic acid in liquorice - evaluation of health hazard. Food Chem Toxicol 1993; 31: 303-312. (Pubitemid 23122371)
46. Saito T et al. An autopsy case of licorice-induced hypokalemic rhabdomyolysis associated with acute renal failure: special reference to profound calcium deposition in skeletal and cardiac muscle. Nippon Jinzo Gakkai Shi 1994; 36: 1308-1314.
47. Gomez-Sanchez E, Gomez-Sanchez C. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol Endocrinol Metab 2006; 263: E1125.